The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib (Q40217698)

From Wikidata

Jump to navigation Jump to search

scientific article published on 2 May 2017

Language	Label	Description	Also known as
English	The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib	scientific article published on 2 May 2017

Statements

scholarly article

1 reference

Europe PubMed Central

18 September 2017

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib (English)

1 reference

Europe PubMed Central

18 September 2017

chronic myeloid leukemia

0 references

Francesco Albano

6

1 reference

Europe PubMed Central

18 September 2017

Maria Teresa Bochicchio

object named as

Maria Teresa Bochicchio

24

0 references

object named as

Carmen Fava

20

0 references

Elisabetta Abruzzese

object named as

Elisabetta Abruzzese

8

0 references

Giuseppe Saglio

object named as

Giuseppe Saglio

27

0 references

object named as

Paolo Vigneri

7

0 references

Mario Tiribelli

object named as

Mario Tiribelli

17

0 references

GIMEMA Working Party on Chronic Myeloid Leukemia

31

object named as

GIMEMA CML Working Party

1 reference

Europe PubMed Central

18 September 2017

Gianantonio Rosti

30

object named as

Gianantonio Rosti

1 reference

Europe PubMed Central

18 September 2017

Fausto Castagnetti

1

object named as

Fausto Castagnetti

1 reference

Europe PubMed Central

18 September 2017

Gabriele Gugliotta

2

object named as

Gabriele Gugliotta

1 reference

Europe PubMed Central

18 September 2017

Michele Baccarani

29

object named as

Michele Baccarani

1 reference

Europe PubMed Central

18 September 2017

Massimo Breccia

3

object named as

Massimo Breccia

1 reference

Europe PubMed Central

18 September 2017

Simona Soverini

23

object named as

Simona Soverini

1 reference

Europe PubMed Central

18 September 2017

12

object named as

Bruno Martino

1 reference

Europe PubMed Central

18 September 2017

18

object named as

Simona Sica

1 reference

Europe PubMed Central

18 September 2017

Massimiliano Bonifacio

19

object named as

Massimiliano Bonifacio

1 reference

Europe PubMed Central

18 September 2017

Francesco Cavazzini

11

object named as

Francesco Cavazzini

1 reference

Europe PubMed Central

18 September 2017

25

object named as

Michele Cavo

1 reference

Europe PubMed Central

18 September 2017

28

object named as

Fabrizio Pane

1 reference

Europe PubMed Central

18 September 2017

Mario Annunziata

15

object named as

Mario Annunziata

1 reference

Europe PubMed Central

18 September 2017

22

object named as

Monica Bocchia

1 reference

Europe PubMed Central

18 September 2017

Patrizia Pregno

14

object named as

Patrizia Pregno

1 reference

Europe PubMed Central

18 September 2017

13

object named as

Ester Orlandi

1 reference

Europe PubMed Central

18 September 2017

16

object named as

Emilio Usala

1 reference

Europe PubMed Central

18 September 2017

Filippo Gherlinzoni

21

object named as

Filippo Gherlinzoni

1 reference

Europe PubMed Central

18 September 2017

5

object named as

Luciano Levato

1 reference

Europe PubMed Central

18 September 2017

10

object named as

Serena Rupoli

1 reference

Europe PubMed Central

18 September 2017

9

object named as

Giuseppe Rossi

1 reference

Europe PubMed Central

18 September 2017

author name string

Alessandra Iurlo

4

1 reference

Europe PubMed Central

18 September 2017

Martinelli Giovanni

26

1 reference

Europe PubMed Central

18 September 2017

publication date

2 May 2017

1 reference

Europe PubMed Central

18 September 2017

American Journal of Hematology

1 reference

Europe PubMed Central

18 September 2017

92

1 reference

Europe PubMed Central

18 September 2017

797-805

1 reference

Europe PubMed Central

18 September 2017

8

1 reference

Europe PubMed Central

18 September 2017

Molecular biology of bcr-abl1-positive chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Standardized definitions of molecular response in chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24774

21 January 2018

Identifiers

10.1002/AJH.24774

1 reference

Europe PubMed Central

18 September 2017

1 reference

Europe PubMed Central

18 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40217698&oldid=2084033613"